viernes, 24 de enero de 2025

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.

https://read.qxmd.com/read/39792928/epcoritamab-plus-gemox-in-transplant-ineligible-relapsed-refractory-dlbcl-results-from-the-epcore-nhl-2-trial?uac=148436CN&ecd=wnl_readmost_250124&sso=true&redirected=slug

No hay comentarios:

Publicar un comentario